ストックスクリーナーアプリを入手
0.8399
9.97%
-0.093
アフターアワーズ：
.84
0.000100
+0.01%
前日終値:
$0.9329
開ける：
$0.89
24時間の取引高:
490.07K
Relative Volume:
0.06
時価総額：
$11.04M
収益：
-
当期純損益:
$-7.51M
株価収益率:
-0.6363
EPS:
-1.32
ネットキャッシュフロー:
$-8.02M
1週間 パフォーマンス:
-18.46%
1か月 パフォーマンス:
-32.27%
6か月 パフォーマンス:
+1.68%
1年 パフォーマンス:
-41.27%
1日の値動き範囲:
$0.814
$0.90
1週間の範囲:
$0.814
$1.05
52週間の値動き範囲:
$0.58
$3.80
Hoth Therapeutics Inc Stock (HOTH) Company Profile
名前
Hoth Therapeutics Inc
セクター
電話
(646)756-2997
住所
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
HOTH を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
0.8399 | 11.04M | 0 | -7.51M | -8.02M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2019-10-15 | 開始されました | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc (HOTH) 最新ニュース
Hoth Therapeutics reports Alzheimer’s drug candidate success By Investing.com - Investing.com South Africa
Hoth Flat on Hookup with Washington Univ. - Baystreet.ca
Hoth Therapeutics reports Alzheimer’s drug candidate success - Investing.com India
Hoth Therapeutics Plans To Advance HT-ALZ Into Clinical Development - MarketScreener
Breakthrough: New Alzheimer's Drug Cuts Key Brain Marker by 15%University Study Reveals - Stock Titan
Revolutionary Alzheimer's Treatment Cuts Brain Amyloid by 15% in Just 20 Hours - Stock Titan
Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from D. Boral Capital - Defense World
Hoth Therapeutics receives USPTO filing receipt for HT-001 patent application - TipRanks
New Patent Filing Strengthens Hoth's Cancer Treatment IP PortfolioKey Details - Stock Titan
Hoth Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Hoth Therapeutics Inc. (HOTH) reports earnings - Quartz
Hoth Therapeutics, Inc. SEC 10-K Report - TradingView
Hoth Therapeutics enhances patent claims, begins toxicity study By Investing.com - Investing.com South Africa
Hoth Therapeutics enhances patent claims, begins toxicity study - Investing.com
Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation - Marketscreener.com
Major Progress: Hoth's Cancer-Fighting Drug Secures Patent Protection and Launches Critical Safety Study - Stock Titan
Hoth Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Hoth Therapeutics (HOTH) Projected to Post Earnings on Thursday - Defense World
Balance Sheet Breakdown: Hoth Therapeutics Inc (HOTH)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Hoth Therapeutics announces ‘positive’ results from study of HT-KIT - Yahoo Finance
Hoth reports progress in GIST treatment with HT-KIT By Investing.com - Investing.com Australia
Hoth reports progress in GIST treatment with HT-KIT - Investing.com India
Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment - PR Newswire
Revolutionary 24-Hour Cancer Treatment Success: Hoth's HT-KIT Destroys GIST Tumors in Breakthrough Study - Stock Titan
Short Interest in Hoth Therapeutics, Inc. (NASDAQ:HOTH) Decreases By 24.8% - Defense World
Hoth Therapeutics to submit HT-001 expanded access application By Investing.com - Investing.com Australia
Hoth Therapeutics Announces Plans To Submit Expanded Access Application For Ht-001 To Support Cancer Patients In Need - Marketscreener.com
Hoth Dips on Drug Application - Baystreet.ca
Hoth Therapeutics to submit Expanded Access application for HT-001 - TipRanks
Hoth Therapeutics to submit HT-001 expanded access application - Investing.com India
Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need - PR Newswire
Hoth Therapeutics reports HT-001 cream success in skin toxicity By Investing.com - Investing.com South Africa
Hoth Therapeutics reports HT-001 cream success in skin toxicity - Investing.com India
Hoth Therapeutics reports ‘promising’ results for HT-001 therapeutic candidate - TipRanks
Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting - PR Newswire
Hoth Therapeutics’ (HOTH) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Hoth Therapeutics Announces Positive Findings On GDNF's Potential As A Game-Changer In Obesity Treatment And Reduced Fatty Liver Disease - MarketScreener
Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease - PR Newswire
GDNF shows promise in obesity treatment, Hoth research finds - Investing.com
Financial Contrast: Emmaus Life Sciences (OTCMKTS:EMMA) and Hoth Therapeutics (NASDAQ:HOTH) - Defense World
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal - MSN
Hoth Therapeutics (NASDAQ:HOTH) Given Buy Rating at D. Boral Capital - Defense World
Hoth Therapeutics to Present at the LD Micro Main Event (XII) - ACCESS Newswire
What to expect from HOTH’s earnings report this quarter? - US Post News
Hoth Therapeutics, OnTargetx R&D Partner to Advance Research for Cancer Therapeutic - Contract Pharma
HOTH's Cancer Breakthrough: Strategic Alliance Accelerates Novel HT-KIT Therapeutic Research - StockTitan
Hoth Therapeutics expands at-the-market offering by $5 million - Investing.com Australia
Research Analysts Set Expectations for HOTH FY2024 Earnings - Defense World
Hoth Therapeutics Inc (HOTH) 財務データ
収益
当期純利益
現金流量
EPS
3.01%
大文字化:
|
ボリューム (24 時間):